Combination of dual-target therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (MCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and… Read More »Combination of dual-target therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer